TrovaGene Inc. (TROV)

0.81 +0.015 (+1.887%)

IEX Real-Time Price

August 17, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 0.795

Price Open 0.783

Volume: 571,737

Avg Volume: 1.18M

Market Cap: 14.33M

P/E Ratio -1.14

52 Wk Range 0.65-12.96



TROV Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
15.79M
539,035
0.69
3.41%

2018-07-13
12.19M
408,854
0.55
3.35%

2018-06-29
12.19M
459,481
0.34
3.77%

2018-06-15
12.19M
345,496
0.32
2.83%




TROV Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-03
Q2 2018
N/A
-0.33 (1)
-0.44
-0.11

2018-05-09
Q1 2018
N/A
-0.08 (1)
0.00
0.00

2018-05-08
Q1 2018
N/A
-0.08 (1)
-0.09
-0.01

2018-03-21
Q4 2017
N/A
-0.13 (1)
0.00
0.00

News

Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial (2018-08-16 08:00 PR Newswire)

SAN DIEGO , Aug. 16, 2018 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV), a clinical-stage oncology therapeutics company, developing targeted therapies for the treatment of leukemias, lymphomas and solid tumor cancers, today announced completion of the second dosing cohort of On…

 


Statistics

Shares Outstanding: 17.69M

Top 15 Institution Percent: 1.30

Price To Sales: 27.03

Price To Book: 0.82

Revenue: 123329

Gross Profit: -349873

Cash: 7.43M

Debt: 1.49M

Return On Assets: -105.97

Return On Equity: -173.32

Profit Margin: N/A

Price History

Beta: -0.21

50-day Moving Avg: 0.81

200-day Moving Avg: 3.61

YTD Change: -77.87

5-day Change: -1.07

1-month Change: 5.61

3-month Change: -75.81

6-month Change: -78.91

1-year Change: -91.67

Revenue Per Share: 0.00

Revenue Per Employee: 7255.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: TrovaGene Inc.

Exchange: NASDAQ Capital Market

Industry: Medical Diagnostics & Research

Sector: Healthcare

Website: http://www.trovagene.com

TrovaGene Inc is clinical-stage, precision medicine oncology therapeutics company. Its focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its Precision Cancer Monitoring technology.